Schema of remission induction, consolidation treatment, and continuation therapy for the first year. Solid arrows indicate triple intrathecal treatment that was administered to all patients and open arrows, additional doses that were administered to patients with an increased risk of CNS relapse. Cranial irradiation plus 5 triple intrathecal treatments were administered only to patients with T-cell immunophenotype and an initial leukocyte count of 100 × 10⁹/L or more or a CNS-3 status. Other details are provided in “Patients, materials, and methods.”